Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Kansas DUSA Pharmaceuticals, Inc. |
---|---|
Information provided by: | University of Kansas |
ClinicalTrials.gov Identifier: | NCT00395187 |
This study will investigate the efficacy of Photodynamic Therapy (PDT), which is the therapeutic use of photochemical reactions, in treating hidradenitis suppurativa (HS), a chronic inflammatory condition affecting areas of skin with sweat glands. We expect that PDT is effective in treating HS.
Condition | Intervention |
---|---|
Hidradenitis Suppurativa |
Procedure: Photodynamic Therapy |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa |
Estimated Enrollment: | 15 |
Study Start Date: | October 2006 |
Study Completion Date: | September 2007 |
This study will investigate the efficacy of PDT using aminolevulinic acid (ALA) and either blue light or intense pulsed light on active lesions of HS. We will attempt to validate the success noted in a previously published case series using PDT with ALA and blue light (Gold, Bridges et al). We will evaluate effect of treatment by number of lesions, global disease severity, and patient self-assessment with the Dermatology Life Quality Index (DLQI).
Detailed informed consent will be obtained prior to treatment at study enrollment. The first four treatment visits will involve clinical evaluation, photography and application of the ALA to the affected area. After a 45 minute incubation period, the area will be washed and then treated with either blue light or intense pulsed light (IPL), depending on body area/investigator choice. One and three-month follow-up visits will involve evaluation of efficacy, but no active treatment.
Gold M, Bridges TM, et al. ALA-PDT and blue light therapy for hidradenitis suppurative. J Drugs Dermatol. 2004; 3 (1 Suppl):S32-5.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Kansas | |
University of Kansas Medical Center | |
Kansas City, Kansas, United States, 66160 |
Principal Investigator: | Daniel Aires, MD | University of Kansas |
Study ID Numbers: | 10514 |
Study First Received: | November 1, 2006 |
Last Updated: | October 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00395187 |
Health Authority: | United States: Institutional Review Board |
Bacterial Infections Skin Diseases, Infectious Skin Diseases Skin Diseases, Bacterial |
Suppuration Hidradenitis Hidradenitis suppurativa Hidradenitis Suppurativa |
Sweat Gland Diseases Infection |